Cutting-Edge Cancer Research for Pets

Pet Care

At BeneVet Oncology, our mission is to revolutionize cancer care for pets, giving beloved companions a fighting chance against one of the most challenging diseases. Founded with a deep commitment to animal health, BeneVet is dedicated to developing innovative, safe, and affordable cancer treatments specifically designed for dogs, cats, and other companion animals. Each year, millions of pets are diagnosed with cancer, yet treatment options remain limited, often adapted from human therapies that may not be fully effective or gentle enough for animals. Our goal is to close this gap by advancing cutting-edge biotechnology and veterinary research tailored to animal health. With a team of experienced veterinary oncologists, pharmaceutical researchers, and animal lovers, we focus on developing targeted therapies that attack cancer cells with fewer side effects, ensuring pets experience the highest quality of life possible. Through rigorous clinical trials, partnerships with veterinary clinics, and an unwavering dedication to scientific excellence, we aim to make cancer treatment accessible and effective for pets around the world. At BeneVet, we believe that pets deserve the same level of care and attention as humans in the fight against cancer. Join us in our mission to bring hope, healing, and extended time together for pets and their families. Together, we can change the future of veterinary cancer care.

Innovating for a Healthier Future for Pets

At BeneVet Oncology, we are dedicated to advancing cancer treatments for pets through cutting-edge technology and innovative research. Our goal is to provide safe, effective, and accessible therapies that enhance the quality of life for pets and their families.

Pet in a laboratory setting
NanoEngineering Icon

NanoEngineering

Leveraging nanoengineered technology to precisely target cancer cells, minimizing side effects.

Cancer Therapy Icon

Targeted Cancer Therapy

Developing treatments that target specific cancer types, increasing effectiveness and safety.

Clinical Trials Icon

Clinical Trials

Conducting trials to test new therapies, ensuring they are safe and effective for pets.

Innovation Icon

Innovation in Veterinary Care

Continuously advancing veterinary oncology to provide the best care for our pets.

Meet Our Team

Manijeh Goldberg

Manijeh Goldberg, Ph.D., M.B.A., M.S

Founder and CEO

Manijeh Goldberg is the Founder and CEO of Privo Technologies, a pioneering biopharmaceutical company revolutionizing localized drug delivery for oncology. With over 20 years of experience, including leadership roles in five startups (one acquired for $475M), she has a proven track record in strategy, fundraising, and commercialization. Under her leadership, Privo has secured significant non-dilutive funding from NIH and NCF, established key partnerships with the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), and advanced multiple clinical-stage therapeutics.


Read More
Dr. Carlos Rodriguez

Dr. Carlos Rodriguez

Principle investigator and Veterinary oncologist

Dr. Carlos O. Rodriguez, Jr. DVM, PhD has been working in specialty practice in Dallas/Fortworth, San Francisco, San Rafael, Berkeley and Sacramento. Between 2003 and 2015, he served as a lecturer in medical oncology at UC Davis where he helped train 15 medical oncologists, two oncology interns and more than 1500 students. His academic endeavors included drug development and pharmacology of anti- neoplastic drugs, aerosol chemotherapy for osteosarcoma, and pegylated arginine deiminase for melanoma. He has authored chapters in oncology textbooks and over 50 scientific articles. He has authored chapters in oncology textbooks and over 50 scientific articles. He has served as chair on both the ACVIM Oncology Exam Committee, and on the grant review committee for Morris Animal Foundation.


Read More